Analisis Biaya untuk Alternatif Transfusi Darah
Hematologi
Early intravenous iron administration in the Emergency Department reduces red blood cell unit transfusion, hospitalisation, re-transfusion, length of stay and costs. (terbuka di window baru)
Sumber: Blood Transfus 2020;18(2):106-16.
Index: PubMed 31855149
DOI: 10.2450/2019.0248-19
https://www.ncbi.nlm.nih.gov/pubmed/31855149 (terbuka di window baru)
Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe. (terbuka di window baru)
Sumber: Support Care Cancer 2013;21(2):485-93.
Index: PubMed 22825456
DOI: 10.1007/s00520-012-1538-0
https://www.ncbi.nlm.nih.gov/pubmed/22825456 (terbuka di window baru)
Restrictive blood transfusion practices are associated with improved patient outcomes. (terbuka di window baru)
Sumber: Transfusion 2014;54(10 Pt 2):2753-9.
Index: PubMed 24995770
DOI: 10.1111/trf.12723
https://www.ncbi.nlm.nih.gov/pubmed/24995770 (terbuka di window baru)
Modeling the cost-effectiveness of prothrombin complex concentrate compared with fresh frozen plasma in emergency warfarin reversal in the United Kingdom. (terbuka di window baru)
Sumber: Clin Ther 2010;32(14):2478-93.
Index: PubMed 21353116
DOI: 10.1016/j.clinthera.2011.01.011
https://www.ncbi.nlm.nih.gov/pubmed/21353116 (terbuka di window baru)
Recombinant activated factor VII use in critically ill infants with active hemorrhage. (terbuka di window baru)
Sumber: J Pediatr Surg 2008;43(12):2235-8.
Index: PubMed 19040942
DOI: 10.1016/j.jpedsurg.2008.08.053
https://www.ncbi.nlm.nih.gov/pubmed/19040942 (terbuka di window baru)
Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia. (terbuka di window baru)
Sumber: Blood Adv. 2022;6(3):785-92.
Index: PubMed 34781363
DOI: 10.1182/bloodadvances.2021005627
https://pubmed.ncbi.nlm.nih.gov/34781363/ (terbuka di window baru)
Blood use in patients receiving intensive chemotherapy for acute leukemia or hematopoietic stem cell transplantation: the impact of a health system-wide patient blood management program. (terbuka di window baru)
Sumber: Transfusion 2017;57(9):2189-96.
Index: PubMed 28671296
DOI: 10.1111/trf.14191
https://www.ncbi.nlm.nih.gov/pubmed/28671296 (terbuka di window baru)
Impact of a conservative red blood cell transfusion strategy in children undergoing hematopoietic stem cell transplantation. (terbuka di window baru)
Sumber: Biol Blood Marrow Transplant 2012;18(5):813-7.
Index: PubMed 22080050
DOI: 10.1016/j.bbmt.2011.10.043
https://www.ncbi.nlm.nih.gov/pubmed/22080050 (terbuka di window baru)
The cost of blood: a study of the total cost of red blood cell transfusion in patients with β-thalassemia using time-driven activity-based costing. (terbuka di window baru)
Sumber: Transfusion 2019;59(11):3386-95.
Index: PubMed 31664712
DOI: 10.1111/trf.15558
https://www.ncbi.nlm.nih.gov/pubmed/31664712 (terbuka di window baru)
Implementation of a patient blood management monitoring and feedback program significantly reduces transfusions and costs. (terbuka di window baru)
Sumber: Transfusion 2015;55(12):2807-15.
Index: PubMed 26264557
DOI: 10.1111/trf.13260
https://www.ncbi.nlm.nih.gov/pubmed/26264557 (terbuka di window baru)
Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (terbuka di window baru)
Sumber: Cancer 2013;119(1):107-14.
Index: PubMed 22744794
DOI: 10.1002/cncr.27686
https://www.ncbi.nlm.nih.gov/pubmed/22744794 (terbuka di window baru)
Budget impact analysis on erythropoiesis-stimulating agents use for the management of chemotherapy-induced anaemia in Greece. (terbuka di window baru)
Sumber: Cost Eff Resour Alloc 2013;11(1):16.
Index: PubMed 23870502
DOI: 10.1186/1478-7547-11-16
https://www.ncbi.nlm.nih.gov/pubmed/23870502 (terbuka di window baru)
Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. (terbuka di window baru)
Sumber: Support Care Cancer 2012;20(1):159-65.
Index: PubMed 21359879
DOI: 10.1007/s00520-010-1083-7
https://www.ncbi.nlm.nih.gov/pubmed/21359879 (terbuka di window baru)
Comparative net cost impact of the utilization of romiplostim and intravenous immunoglobulin for the treatment of patients with immune thrombocytopenia in Québec, Canada. (terbuka di window baru)
Sumber: J Med Econ 2013;16(2):318-26.
Index: PubMed 23216012
DOI: 10.3111/13696998.2012.756400
https://www.ncbi.nlm.nih.gov/pubmed/23216012 (terbuka di window baru)
Blood transfusion versus hydroxyurea in beta-thalassemia in Iran: a cost-effectiveness study. (terbuka di window baru)
Sumber: Hematology 2018;23(7):417-22.
Index: PubMed 29157136
DOI: 10.1080/10245332.2017.1404262
https://www.ncbi.nlm.nih.gov/pubmed/29157136 (terbuka di window baru)
The burden of blood transfusion: a utilization and economic analysis--a pilot study in patients with chemotherapy-induced anemia (CIA). (terbuka di window baru)
Sumber: J Med Econ 2013;16(5):633-8.
Index: PubMed 23425291
DOI: 10.3111/13696998.2013.778269
https://www.ncbi.nlm.nih.gov/pubmed/23425291 (terbuka di window baru)
Prospective monitoring of plasma and platelet transfusions in a large teaching hospital results in significant cost reduction. (terbuka di window baru)
Sumber: Transfusion 2010;50(2):487-92.
Index: PubMed 19804569
DOI: 10.1111/j.1537-2995.2009.02413.x
https://www.ncbi.nlm.nih.gov/pubmed/19804569 (terbuka di window baru)
Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease. (terbuka di window baru)
Sumber: Am J Hematol 2010;85(10):795-7.
Index: PubMed 20645429
DOI: 10.1002/ajh.21772
https://www.ncbi.nlm.nih.gov/pubmed/20645429 (terbuka di window baru)
Increased hospital costs associated with red blood cell transfusion. (terbuka di window baru)
Sumber: Transfusion 2015;55(5):1082-9.
Index: PubMed 25488623
DOI: 10.1111/trf.12958
https://www.ncbi.nlm.nih.gov/pubmed/25488623 (terbuka di window baru)